Novartis to acquire Spinifex, continue pain drug development

handshake: Medicines australia/Govt letter of agreement
Novartis is to acquire Spinifex Pharmaceuticals, a company focused on the development of new drugs for treating chronic pain. Spinifex Pharmaceuticals, Inc. and its Australian subsidiary Spinifex Pharmaceuticals Pty Ltd, has announced agreement to the sale of Spinifex to Novartis International AG for an upfront cash consideration of US$200 million plus significant further development and

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous MERS: thanks to international travel, Australia's not immune
Next Cancer trials app launched in Victoria